The authors reported that the identified peptide improved hepatic insulin resistance (IR) through enhancing glycogen synthesis and glucose uptake and reducing gluconeogenesis via activating the IRS-1/PI3K/Akt and AMPK signaling pathways in hepatic HepG2 cells [75]. The gene discussed is AKT1; the disease is Insulin resistance.